SCHEMBL414134

SCHEMBL414134

Brc1ccc2cc[nH]c2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.45
AXL P30530 2/20 0.45
NUDT1 P36639 1/20 0.45
AHR P35869 2/20 0.40
BRD4 O60885 1/20 0.39
PRKCI P41743 1/20 0.38
APP P05067 1/20 0.37
CYP2A6 P11509 2/20 0.35
NR4A2 P43354 1/20 0.35
ADORA2A P29274 2/20 0.34
ADORA1 P30542 2/20 0.34
DYRK1A Q13627 1/20 0.34
ESR1 P03372 2/20 0.33
CDK8 P49336 1/20 0.33
CCNT1 O60563 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
CCNA1 P78396 1/20 0.33
CDK5 Q00535 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29362558 1.00 MAPK1 (0.45) MAPK1AXLNUDT1AHRBRD4
SCHEMBL28358707 0.98 MAPK1 (0.44) MAPK1AXLNUDT1AHRBRD4
SCHEMBL28358709 0.96 MAPK1 (0.42) MAPK1AXLNUDT1AHRBRD4
Ethoxycarbonyl Group SCHEMBL27554420 0.80 BRD4 (0.35) MAPK1AXLNUDT1BRD4
SCHEMBL12798351 0.76 AXL (0.45) MAPK1AXLNUDT1AHRBRD4
SCHEMBL28019464 0.74 PARP1 (0.39) MAPK1AHRCYP2A6NR4A2DYRK1A
SCHEMBL1045770 0.73
SCHEMBL684703 0.71 AXL (0.45) MAPK1AXLNUDT1AHRBRD4
SCHEMBL343400 0.71 ADORA2A (0.57) MAPK1AXLNUDT1BRD4PRKCI
SCHEMBL4063067 0.71 AXL (0.45) MAPK1AXLNUDT1AHRBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107513062-A A kind of preparation method of the 7-azaindole derivatives of 6 bromine 7 湖南华腾制药有限公司 2017-12-26 CN claimed
WO-2015011008-A1 7-AZAINDOLE DERIVATIVES AS PARP INHIBITORS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2015-01-29 WO claimed
US-20260124214-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2026-05-07 US disclosed
US-20260116903-A1 AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-04-30 US disclosed
US-20260035362-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC (CN) 2026-02-05 US disclosed
US-12540149-B2 Aromatic heterocyclic compound, pharmaceutical composition, and use thereof RECURSION PHARMACEUTICALS, INC. (US) 2026-02-03 US disclosed
US-12528792-B2 Sulfonamide compounds and the use thereof in the treatment of cancer TroBio Therapeutics Pty Ltd (AU) 2026-01-20 US disclosed
US-20250339444-A1 Methods and Compositions for Treating Fatty Liver and Viral Infections UNIV LELAND STANFORD JUNIOR (US) 2025-11-06 US disclosed
EP-4587427-A1 COMPOUNDS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCERS BenevolentAI Cambridge Limited (GB) 2025-07-23 EP disclosed
US-12365670-B2 GLP-IR agonists and uses thereof QILU REGOR THERAPEUTICS INC. (CN) 2025-07-22 US disclosed
US-20250115606-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2025-04-10 US disclosed
US-20070049615-A1 Compounds and methods for development of Ret modulators PLEXXIKON, INC. 2007-03-01 US disclosed
US-20070049615-A1 Compounds and methods for development of Ret modulators PLEXXIKON, INC. 2007-03-01 US disclosed
WO-2007002433-A1 PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-01-04 WO disclosed
WO-2007002433-A1 PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-01-04 WO disclosed
WO-2006128692-A2 2-OXO-1-PYRROLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed
WO-2006128693-A2 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM UCB PHARMA, S.A. (BE) 2006-12-07 WO disclosed
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA & UPJOHN (IT) 2003-01-02 US disclosed
US-6486322-B1 Azaindole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA ITALIA S.P.A. (IT) 2002-11-26 US disclosed
US-6335342-B1 1H-PYRROLO(2,3-B)PYRIDINE DERIVATIVES; ANTICARCINOGENIC, ANTIMETASTASIS, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS PHARMACIA & UPJOHN S.P.A. (IT) 2002-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035362-A1 GLP-1R AGONISTS AND USES THEREOF GLP1R, GPR119, IAPP MAPK1 128/4885AXL 1564/4885NUDT1 4513/4885
US-20260124214-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAPK1 2157/4885AXL 2669/4885NUDT1 1275/4885
US-12365670-B2 GLP-IR agonists and uses thereof GLP1R, GPR119, GIPR MAPK1 2027/4885AXL 1463/4885NUDT1 3670/4885
US-20250115606-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR MAPK1 736/4885AXL 1528/4885NUDT1 1006/4885
US-12540149-B2 Aromatic heterocyclic compound, pharmaceutical composition, and use thereof CDK7, CDK17, CDK1 MAPK1 610/4885AXL 1612/4885NUDT1 2183/4885
US-20260116903-A1 AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF CDK7, CDK8, CDK6 MAPK1 578/4885AXL 1089/4885NUDT1 1482/4885
US-20250339444-A1 Methods and Compositions for Treating Fatty Liver and Viral Infections FABP1, FABP4, LIPC MAPK1 4861/4885AXL 4657/4885NUDT1 3777/4885
US-20030004350-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS FFAR4, AZI2, CNKSR1 MAPK1 244/4885AXL 307/4885NUDT1 342/4885
US-20070049615-A1 Compounds and methods for development of Ret modulators RET, GFRA1, GFRA3 MAPK1 1057/4885AXL 73/4885NUDT1 2980/4885
US-12528792-B2 Sulfonamide compounds and the use thereof in the treatment of cancer SLC10A6, SLCO4C1, SLCO2A1 MAPK1 1353/4885AXL 32/4885NUDT1 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.